Lataa...
Triple-negative breast cancer: is there a treatment on the horizon?
Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5352107/ https://ncbi.nlm.nih.gov/pubmed/27765921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12284 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|